Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 AlteredExpression BEFREE HER2 is a receptor tyrosine kinase, which is amplified and overexpressed in a subset of human cancers including breast and gastric cancers, and is indicated in its involvement in progression of cancer. 28639750

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Amplification of the HER2 gene is an indicator of poor prognosis for several kinds of malignancies such as breast and gastric cancer, and anti-HER2 targeting therapies provide clinical benefits in these patients. 28363756

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor. 29143776

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Comparison of Clinicopathologic Parameters and Survivals Between Epstein-Barr Virus-positive and Her2-positive Gastric Cancers. 26945448

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE HER2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks. 28513868

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Human epidermal growth factor receptor 2 (Her2, an orphan receptor of ErbB family) is considered as an important biomarker as it plays a key role in the development and progression of aggressive types of breast, ovarian, stomach and gastric cancer. 28224267

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Trastuzumab in combination with chemotherapy is the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancers. 28223426

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. 28899363

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. 28508152

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE In addition, molecular therapy has been designed to target biomarkers such as growth factors (human epidermal growth factor receptor 2, VEGF) and chemokines, although they have not clearly proven to be effective in inhibiting GC metastasis in clinical trials. 26937132

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and c-MET status are independent prognostic factors for advanced gastric cancer patients who received standard chemotherapy. 25682441

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 AlteredExpression BEFREE A total of 133 patients undergoing surgical resection for GC between March 2006 and January 2009 in the Second Affiliated Hospital of Wenzhou Medical University were included in this study. c-erbB-2 protein expression was determined by immunohistochemistry. 26549693

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Human epidermal growth factor receptor 2 (HER2) overexpression and amplification have been reported as predictive markers for HER2-targeted therapy in breast and gastric cancer, whereas human epidermal growth factor receptor 3 (HER3) is emerging as a potential resistance factor. 27981460

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. 25512144

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. 26970343

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. 26846307

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Trastuzumab-resistant (HR) subclones derived from 3 HER2-overexpressing gastric cancer cells were generated and characterized for alterations in HER2-signaling mechanisms by next-generation sequencing, immunohistochemical, western blot and qRT-PCR techniques, and molecular modeling analysis. 26919099

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 AlteredExpression BEFREE HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). 24993498

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 AlteredExpression BEFREE HER2 overexpression/amplification is linked to trastuzumab response in breast/gastric cancers. 26690310

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Additionally, as the ceRNA of miR-331-3p, HOTAIR may modulate HER2 deregulation in gastric cancer cells. 25640751

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. 26752196

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 GeneticVariation BEFREE Interaction and pathway analysis identified extracellular signal regulated kinase (ERK) cascade and actin polymerization and actinmyosin assembly contraction as pathways of importance in ERBB2+ and ERBB2- gastric cancer samples, respectively. 26435392

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 GeneticVariation BEFREE All 37,992 patients were tested by immunohistochemistry (IHC); 21,642 of them were also examined for HER2 amplification with either fluorescent in situ hybridization (FISH) (11,670 patients) or chromogenic in situ hybridization (CISH) (9,972 patients); 18,262 patients had tumors other than breast or gastric cancer. 25712293

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE MET amplification, but not EGFR and ErbB2, was a significant prognostic factor in poor survival among patients with gastric cancer. 25820598

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.600 Biomarker BEFREE Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling. 26173505

2016